The Anemia of Inflammation/Malignancy: Mechanisms and Management

Hillman RS, Finch CA. Red Cell Manual. 7th Edition. Philadelphia, PA: FA Davis; 1997:190.

Miller CB, Jones RJ, Piantodosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322:1689–1692.

Roy CN, Mak H, Akpan I, et al. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007;109:4038–4044.

Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73–78.

Lee GR. The anemia of chronic disease. Semin Hematol. 1983;20:61–80.

Cash JM, Sears DA. The spectrum of disease associated with the anemia of chronic disease: a study of 90 cases. Am J Med. 1990;87:638–644.

Means RT. Pathogenesis of the anemia of chronic disease: a cytokine mediated anemia. Stem Cells. 1995;13:32–37.

Weiss G, Goodnough LT. Anemia of chronic disease [review]. N Engl J Med. 2005;352:1011–1023.

Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. Am J Clin Oncol. 1993;16:22–25.

Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol. 1992;19:29–35.

Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol. 1994;21:21–28.

Wood PA, Hrusheshky WJM. Cysplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95:1650–1659.

Goldberg MA, Glass GA, Cunningham JM, Bunn HF. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci U S A. 1987;84:7972–7976.

Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987–1994.

Jelkmann W, Pagel H, Wolff M, et al. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci. 1991;50:301–308.

Corazza F, Beguin Y, Bergmann P, et al. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood. 1998;92:1793–1798.

Zanjani ED, McGlave PB, Davies SF, et al. In vitro suppression of erythropoiesis by bone marrow adherent cells from some patients with fungal infections. Br J Haematol. 1982;50:479–490.

Roodman GD, Horadam VW, Wright TL. Inhibition of erythroid colony formation by autologous bone marrow adherent cells from patients with the anemia of chronic disease. Blood. 1983;62:406–412.

Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of tumor necrosis factor on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-γ J Immunology. 1986;136:4487–4495.

Means RT, Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol. 1992;150:59–64.

Means RT, Dessypris EN, Krantz SB. Inhibition of human colony-forming units erythroid by tumor necrosis factor requires accessory cells. J Clin Invest. 1990;86:538–541.

Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest. 1993;91:416–419.

Means RT, Krantz SB, Luna J, et al. Inhibition of murine erythroid colony formation in vitro by gamma interferon and correction by interferon inhibitor. Blood. 1994;83:911–915.

Johnson CS, Keckler DJ, Topper MI, et al. In vivo hematopoietic effects of recombinant interleukin-1α in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood. 1989;73:678–683.

Johnson RA, Waddelow TA, Caro J, et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood. 1989;74:130–138.

Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor. Exp Hematol. 1996;24:204–208.

Dallalio G, Law E, Means RT. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood. 2006;107:2702–2704.

Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood. 2002;100:474–482.

Papadaki HA, Kritikos HD, Gemetzi C, et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood. 2002;99:1610–1619.

Nicolas G, Viatte L, Bennoun M, et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis. 2002;29:327–335.

Peyssonnaux C, Zinkernagel S, Datta V, et al. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood. 2006;107:3727–3732.

Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111:2392–2399.

Elin RJ, Wolff SM, Finch CA. Effect of induced fever on serum iron and ferritin concentrations in man. Blood. 1977;49:147–153.

Cazzola M, Ponchio L, de Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996;87:4824–4830.

Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin gene expression. Nat Genet. 2006;38:531–539.

Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271–1276.

Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood2006;108:3204–3209.

Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPá. Blood. 2008;111:5727–5733.

Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–895.

Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606–2647.

Littlewood TJ, Bajetta E, Nortrier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy; results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874.

Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260.

Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027–1032.

Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960–5972.

Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin adminstration for the treatment of cancer-associated anemia. J Amer Med Assoc. 2008;299:914–924.

Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-induced anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–1307.

Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231–242.

Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627–632.

Bastit L, Vendebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26:1611–1618.

Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol. 2008;26:1619–1625.

Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol. 2008;26:1579–1581.